Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease

被引：234
作者：
Michos, Erin D. [1 ]
McEvoy, John W. [2 ]
Blumenthal, Roger S. [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Ciccarone Ctr Prevent Cardiovasc Dis, Baltimore, MD USA
[2] Natl Univ Ireland, Natl Inst Prevent & Cardiovasc Hlth, Galway, Ireland
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2019年 / 381卷 / 16期
关键词：
DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-ARTERY CALCIUM; STATIN THERAPY; AMERICAN-COLLEGE; LDL-CHOLESTEROL; FOLLOW-UP; RISK REDUCTION; ASSOCIATION; PCSK9; EFFICACY;
D O I：
10.1056/NEJMra1806939
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Management of serum cholesterol level is a central objective in preventing cardiovascular events. Current guidelines recommend calculation of cardiovascular risk, with treatment decisions based on these data and clinician-patient discussion of risk. Statins remain the first line of pharmacotherapy.
引用
收藏
页码：1557 / 1567
页数：11
相关论文
共 66 条
  • [1] Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
    Abdelhamid, Asmaa S.
    Brown, Tracey J.
    Brainard, Julii S.
    Biswas, Priti
    Thorpe, Gabrielle C.
    Moore, Helen J.
    Deane, Katherine H. O.
    AlAbdulghafoor, Fai K.
    Summerbell, Carolyn D.
    Worthington, Helen V.
    Song, Fujian
    Hooper, Lee
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (11):
  • [2] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [3] [Anonymous], 2018, ARCH BRONCONEUMOL, V5, P5
  • [4] [Anonymous], 2016, JAMA-J AM MED ASSOC, V316, P1997, DOI DOI 10.1001/jama.2016.15450
  • [5] [Anonymous], 2015, DIABETOL KLIN SA, V4, pA1
  • [6] Arnett DK, 2019, CIRCULATION, V140, pE563, DOI [10.1161/CIR.0000000000000678, 10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.010, 10.1016/j.jacc.2019.03.009]
  • [7] Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2
    Arps, Kelly
    Pallazola, Vincent A.
    Cardoso, Rhanderson
    Meyer, Joseph
    Jones, Richard, II
    Latina, Jacqueline
    Gluckman, Ty J.
    Stone, Neil J.
    Blumenthal, Roger S.
    McEvoy, John W.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2019, 132 (07) : E599 - E609
  • [8] Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1
    Arps, Kelly
    Pallazola, Vincent A.
    Cardoso, Rhanderson
    Meyer, Joseph
    Jones, Richard, II
    Latina, Jacqueline
    Gluckman, Ty J.
    Stone, Neil J.
    Blumenthal, Roger S.
    McEvoy, John W.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2019, 132 (06) : E569 - E580
  • [9] Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial
    Arrieta, Alejandro
    Hong, Jonathan C.
    Khera, Rohan
    Virani, Salim S.
    Krumholz, Harlan M.
    Nasir, Khurram
    [J]. JAMA CARDIOLOGY, 2017, 2 (12) : 1369 - 1374
  • [10] Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases
    Arsenault, Benoit J.
    Perrot, Nicolas
    Puri, Rishi
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (02) : 257 - 268
1234567